Almirall Drug Patent Portfolio
Almirall owns 8 orange book drugs protected by 33 US patents with Solage having the least patent protection, holding only 2 patents. And Klisyri with maximum patent protection, holding 8 patents. Given below is the list of Almirall's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10669236 | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide | 07 Sep, 2038 | Active |
| US10617693 | Methods of treating and/or preventing actinic keratosis | 12 Mar, 2038 | Active |
| US11497750 | Methods of treating and/or preventing actinic keratosis | 12 Mar, 2038 | Active |
| US11273132 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof | 18 Nov, 2033 | Active |
| US9161926 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof | 18 Nov, 2033 | Active |
| US9517219 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof | 18 Nov, 2033 | Active |
| US9255068 | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same | 09 Feb, 2033 | Active |
| US8318706 | Substituted tetracycline compounds | 01 May, 2031 | Active |
| US8513223 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | 07 Dec, 2029 | Active |
| US7851470 | Composition and methods for modulating a kinase cascade | 02 Feb, 2029 | Active |
| US9481639 | Substituted tetracycline compounds for treatment of inflammatory skin disorders | 10 Aug, 2028 | Active |
| US10323001 | Compositions for modulating a kinase cascade and methods of use thereof | 28 Dec, 2027 | Active |
| US8460641 | Microemulsion process and composition | 13 Aug, 2027 | Active |
| US7875630 | Process salts compositions and use | 14 Feb, 2027 | Active |
| US7300931 | Compositions for treating cell proliferation disorders | 06 Feb, 2026 | Active |
| US8236799 | Biaryl compositions and methods for modulating a kinase cascade | 28 Dec, 2025 | Active |
| US8980890 | Compositions and methods of treating cell proliferation disorders | 28 Dec, 2025 | Active |
| US9492384 | Microemulsion and sub-micron emulsion process and compositions | 31 Aug, 2025 | Active |
| US8962000 | Microemulsion and sub-micron emulsion process and compositions | 31 Aug, 2025 | Active |
| US8207191 | Process, salts, composition and use | 30 Aug, 2024 | Expired |
| USRE39128 | Pleuromutilin derivatives as antimicrobials | 12 Apr, 2021 | Expired |
| USRE43390 | Pleuromutilin derivatives as antimicrobials | 12 Apr, 2021 | Expired |
| US8232276 | Anhydrous topical skin preparations | 24 Nov, 2020 | Expired |
| US6353029 | Storage stable tretinoin and 4-hydroxyanisole containing topical composition | 24 Aug, 2020 | Expired |
| US6730288 | Mousse composition | 08 Sep, 2019 | Expired |
| US7029659 | Mousse composition | 08 Sep, 2019 | Expired |
| US7179475 | Anhydrous topical skin preparations | 04 Dec, 2018 | Expired |
| US8735393 | Anhydrous topical skin preparations | 04 Dec, 2018 | Expired |
| US5863560 | Compositions and methods for topical application of therapeutic agents | 11 Sep, 2016 | Expired |
| US6060085 | Compositions and methods for topical application of therapeutic agents | 11 Sep, 2016 | Expired |
| US6620435 | Compositions for topical application of therapeutic agents | 11 Sep, 2016 | Expired |
| US5690923 | Stable topical retinoid compositions | 25 Nov, 2014 | Expired |
| US5194247 | Synergistic skin depigmentation composition | 10 Dec, 2013 | Expired |
Latest Legal Activities on Almirall's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Almirall.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 May, 2024 | US8318706 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 May, 2024 | US9481639 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9492384 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9492384 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Mar, 2024 | US8232276 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US7300931 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US7851470 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US7300931 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US7851470 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236799 |
| Requirement for information sent under 37 CFR 1.750 | 23 Jan, 2024 | US8318706 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US8318706 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Dec, 2023 | US8207191 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US8318706 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Nov, 2023 | US10669236 |
Almirall's Drug Patent Litigations
Almirall's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 22, 2009, against patent number US8232276. The petitioner , challenged the validity of this patent, with Katherine M. Burnett et al as the respondent. Click below to track the latest information on how companies are challenging Almirall's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9517219 | November, 2018 |
FWD Entered
(29 May, 2020)
| Almirall, LLC | Amneal Pharmaceuticals LLC |
| US9517219 | June, 2019 |
FWD Entered
(29 May, 2020)
| Almirall, LLC | Mylan Pharmaceuticals Inc. |
| US9161926 | February, 2018 |
FWD Entered
(27 Aug, 2019)
| Almirall, LLC | Amneal Pharmceuticals LLC |
| US8232276 | June, 2009 |
Decision
(17 May, 2010)
| Katherine M. Burnett et al | |
Almirall Drug Patents' Oppositions Filed in EPO
Almirall drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 14, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP05775966A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP05775966A | May, 2014 | Henkel AG & Co. KGaA | Patent maintained as amended |
| EP05775966A | May, 2014 | Generics [UK] Limited | Patent maintained as amended |
Almirall's Family Patents
Almirall Drug List
Given below is the complete list of Almirall's drugs and the patents protecting them.
1. Aczone
Aczone is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11273132 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
18 Nov, 2033
(8 years from now)
| Active |
| US9161926 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
18 Nov, 2033
(8 years from now)
| Active |
| US9517219 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
18 Nov, 2033
(8 years from now)
| Active |
| US5863560 | Compositions and methods for topical application of therapeutic agents |
11 Sep, 2016
(8 years ago)
| Expired |
| US6060085 | Compositions and methods for topical application of therapeutic agents |
11 Sep, 2016
(8 years ago)
| Expired |
| US6620435 | Compositions for topical application of therapeutic agents |
11 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aczone's drug page
2. Altabax
Altabax is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7875630 | Process salts compositions and use |
14 Feb, 2027
(1 year, 9 months from now)
| Active |
| US8207191 | Process, salts, composition and use |
30 Aug, 2024
(8 months ago)
| Expired |
| USRE39128 | Pleuromutilin derivatives as antimicrobials |
12 Apr, 2021
(4 years ago)
| Expired |
| USRE43390 | Pleuromutilin derivatives as antimicrobials |
12 Apr, 2021
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Altabax's drug page
3. Klisyri
Klisyri is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10669236 | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
07 Sep, 2038
(13 years from now)
| Active |
| US10617693 | Methods of treating and/or preventing actinic keratosis |
12 Mar, 2038
(12 years from now)
| Active |
| US11497750 | Methods of treating and/or preventing actinic keratosis |
12 Mar, 2038
(12 years from now)
| Active |
| US7851470 | Composition and methods for modulating a kinase cascade |
02 Feb, 2029
(3 years from now)
| Active |
| US10323001 | Compositions for modulating a kinase cascade and methods of use thereof |
28 Dec, 2027
(2 years from now)
| Active |
| US7300931 | Compositions for treating cell proliferation disorders |
06 Feb, 2026
(8 months from now)
| Active |
| US8236799 | Biaryl compositions and methods for modulating a kinase cascade |
28 Dec, 2025
(7 months from now)
| Active |
| US8980890 | Compositions and methods of treating cell proliferation disorders |
28 Dec, 2025
(7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Klisyri's drug page
4. Seysara
Seysara is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9255068 | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
09 Feb, 2033
(7 years from now)
| Active |
| US8318706 | Substituted tetracycline compounds |
01 May, 2031
(5 years from now)
| Active |
| US8513223 | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
07 Dec, 2029
(4 years from now)
| Active |
| US9481639 | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
10 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Seysara's drug page
5. Solage
Solage is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6353029 | Storage stable tretinoin and 4-hydroxyanisole containing topical composition |
24 Aug, 2020
(4 years ago)
| Expired |
| US5194247 | Synergistic skin depigmentation composition |
10 Dec, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Solage's drug page
Explore Our Curated Drug Screens
6. Veltin
Veltin is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9492384 | Microemulsion and sub-micron emulsion process and compositions |
31 Aug, 2025
(3 months from now)
| Active |
| US5690923 | Stable topical retinoid compositions |
25 Nov, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veltin's drug page
7. Verdeso
Verdeso is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8460641 | Microemulsion process and composition |
13 Aug, 2027
(2 years from now)
| Active |
| US8962000 | Microemulsion and sub-micron emulsion process and compositions |
31 Aug, 2025
(3 months from now)
| Active |
| US9492384 | Microemulsion and sub-micron emulsion process and compositions |
31 Aug, 2025
(3 months from now)
| Active |
| US6730288 | Mousse composition |
08 Sep, 2019
(5 years ago)
| Expired |
| US7029659 | Mousse composition |
08 Sep, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Verdeso's drug page
8. Xolegel
Xolegel is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8232276 | Anhydrous topical skin preparations |
24 Nov, 2020
(4 years ago)
| Expired |
| US7179475 | Anhydrous topical skin preparations |
04 Dec, 2018
(6 years ago)
| Expired |
| US8735393 | Anhydrous topical skin preparations |
04 Dec, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xolegel's drug page